Evaluating IL22RA1 expression as a predictive indicator in human colon cancer progression

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Colon cancer is a leading cause of cancer-related deaths globally.
• Current treatments have limitations, and immunotherapy benefits only a subset of patients.
• Understanding the tumor immune microenvironment is crucial for developing novel therapies.

Purpose of the Study:

• To investigate the expression patterns and prognostic significance of IL22RA1, IL22, CD155, and IL22BP in colon cancer.
• To evaluate the potential of IL22RA1 as a prognostic biomarker and therapeutic target in colon cancer.

Main Methods:

• Multi-color immunohistochemistry (mIHC) on 90 colon cancer tissue microarrays (TMAs).
• Assessment of IL22RA1, IL22, CD155, and IL22BP expression, localization, and clinical relevance.
• Analysis of overall survival (OS) based on expression levels and correlation with immune cell infiltration.

Main Results:

• IL22RA1, CD155, and IL22BP expression were significantly higher in colon cancer tissues than normal tissues.
• High IL22RA1 expression was associated with significantly worse overall survival (OS).
• Co-expression of IL22RA1 with IL22 or CD155 predicted poorer OS, while low IL22RA1 with high IL22BP predicted better OS.
• High IL22RA1 expression correlated with diminished infiltration of key T cell subsets, including CD8+ and CD4+ T cells.

Conclusions:

• Elevated IL22RA1 expression in colon cancer is an independent risk factor for poor prognosis.
• IL22RA1's interaction with IL22 and CD155 may drive tumorigenesis and impact patient outcomes.
• IL22RA1 shows promise as a prognostic biomarker and a potential immunotherapeutic target for colon cancer.